

INNOVA CAPTAB LIMITED
1281/1, Hilltop Industrial Estate, Near
EPIP, Phase-I, Jharmajri, Baddi, Dist.
Solan (H.P.)-173205 India.
Phone: +91-1795-650820



August 9, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, "G" Block
Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ('SEBI LODR Regulations'), we are enclosing herewith the Press Release issued by the Company on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2024.

The Press Release is available on the website of the Company at www.innovacaptab.com

This is for your information and record.

Thanking you,

Yours faithfully,
For **Innova Captab Limited**

Neeharika Shukla
Company Secretary & Compliance Officer
Membership No.: A42724

Encl.: As above



INNOVA CAPTAB LIMITED

PRESS RELEASE

Performance Review of Q1' FY 25

Innova Captab Limited posted a strong set of numbers for Q1' FY 25 with Revenue from Operations at ₹ 294.3 crore and Profit After Tax at ₹ 29.5 crore,

Registered a Y-o-Y Revenue growth of 26% and PAT growth of 68%

Mumbai: 9th August 2024: Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports has announced its financial results for the first quarter ended June 30,2024.

Financial Performance: Q1'FY 25 v/s Q1'FY 24

- Revenue from operation is ₹ **294.3 Crore** in Q1'FY 25 as against ₹ **233.2 Crore** of Q1'FY 24 registering a growth of **26%**.
- The Company's EBITDA stood at ₹ **44.3 Crore** in Q1'FY 25 against ₹ **32.4 Crore** of Q1'FY 24 registering a growth of **37%**.
- Profit After Tax (PAT) stood at ₹ **29.5 Crore** in Q1'FY 25 against ₹ **17.6 Crore** of Q1'FY 24 registering a growth of **68%**.

Commenting on the results, **Vinay Lohariwala, Managing Director, - Innova Captab Limited** said, For Q1FY25, we reported a total income of Rs 296 crores, a 27% growth compared to same quarter previous year. All business areas are experiencing healthy growth and are expected to maintain this momentum in the coming quarters.

Over the past 3-4 years, our revenue has grown at a robust growth rate. With the new Jammu facility, we are optimistic about sustaining this growth trajectory over the next few years.

As a company, we remain committed to driving sustainable growth by exploring new opportunities and focusing on value-added products. The Indian pharmaceutical sector is poised for significant growth in the mid to long term, with both domestic and global MNCs are increasingly seeking reliable and sustainable suppliers like us.

About Innova Captab Ltd : <https://www.innovacaptab.com> :

The foundation of Innova is their in-house research and development which helps to focus on building complex product portfolio. As a major CDMO player, Innova caters to India's top 14 out of 15 pharmaceuticals companies and have license to manufacture products through four state of the art manufacturing facilities at Baddi - Himachal Pradesh, Dehradun - Uttarakhand and at Taloja - Maharashtra while maintaining WHO-GMP, EU-GMP, UK-MHRA and other major registrations with these facilities.

By Q2'FY 25, the upcoming greenfield plant in Jammu is expected to be commercialized. This facility will have four production blocks: cephalosporin, penicillin, penum and BFS and will manufacture oral solid dosages, dry powder injections, dry syrup, BFS, Large Volume Parenterals and respiratory respule products.

For more information, contact:

Mr. Lokesh Bhasin
Email : investors@innovacaptab.com
www.innovacaptab.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.